Eye health company Bausch + Lomb Corporation (NYSE: BLCO) (TSX: BLCO) announced on Wednesday that it will present new scientific data and host educational events at the European Dry Eye Society (EuDEC) 2024 Congress in Madrid, Spain, from 20-22 June 2024.
Presentations will include results from several studies on consumer, pharmaceutical and vision care products from Bausch + Lomb's extensive eye care portfolio. These studies evaluate the treatment landscape and overall disease burden of dry eye.
Educational sessions will spotlight innovations in diagnosing and treating dry eye, focusing on technological advancements.
Key presentations include:
Poster presentations:
"Evaluation of the Safety of a Novel Preservative-Free Formulation of Brimonidine Tartrate Ophthalmic Solution" by Orobia et al.
"Ocular Vasoconstrictors: Does Mechanism of Action Make a Difference?" by Siebelmann et al.
"Conjunctival Hyperemia: Healthcare Professionals' Perspectives on the Treatment Landscape in Europe" by Borges et al.
"Comparison of Two Preservative-Free Artificial Tears with Sodium Hyaluronate for Relief of Dry Eye: Multicenter Trial Findings" by Labetoulle et al.
"Using Narrative Medicine to Identify Key Factors Affecting Quality of Life in Dry Eye Disease" by Rolando et al.
Oral presentation on 22 June:
"Patient Communication and Unmet Needs Session: Narrative Medicine in Dry Eye - Exploring the Burden of the Disease" by Dr. Maurizio Rolando, 09:00-09:10 a.m. CEST, Conference Room 1.
Featured educational events on 22 June:
"Innovating with Bausch + Lomb: Driving Breakthroughs in Ophthalmic Technology" by Dr. Mohamed Yassine, Bausch + Lomb Vice President, Global Medical & Scientific Affairs, 11:30-12:00 p.m. CEST, Conference Room 2.
"The Patient-Centric Approach to Dry Eye: Innovations in Clinical Diagnosis and Treatment" by Prof. José Benítez-del-Castillo, 1:45-2:30 p.m. CEST, Conference Room 1.
Founded in 1853, Bausch + Lomb offers a comprehensive portfolio of approximately 400 products, including contact lenses, lens care products, ophthalmic pharmaceuticals, over-the-counter products and surgical devices. The company, headquartered in Vaughan, Ontario, with offices in Bridgewater, New Jersey, has 13,000 employees and a presence in nearly 100 countries.
Johnson & Johnson agrees acquisition of V-Wave
Nightingale Health gains UKCA certification and expands with new laboratory
Talphera enrols first subject in NEPHRO CRRT study
China Pharma Holdings anticipates launch of Dry Eye Disease Therapeutic Device in early 2025
SOPHiA DDM Platform achieves IVDR certification, enhancing diagnostic precision
Medtronic reports FDA approval of Simplera CGM; partners with Abbott
OncoBeta expands Rhenium-SCT (Skin Cancer Therapy) treatment services in Italy
Labcorp's PGDx elio plasma focus Dx receives US FDA De Novo marketing authorisation
Verici Dx announces completion of Thermo Fisher Scientific licensing agreement
Polarean Imaging enters into trade-in agreement with University of Kansas Medical Center